Want to see JP:6678 full AI Analyst Report?
6678 Stock Chart & Stats
¥2245.00
-¥13.00(-0.72%)
At close: 4:00 PM EST
¥2245.00
-¥13.00(-0.72%)
Day’s Range― - ―
52-Week Range¥1,830.00 - ¥2,787.00
Previous CloseN/A
Volume3.70K
Average Volume (3M)5.40K
Market Cap
¥16.79B
Enterprise Value¥4.29B
Total Cash (Recent Filing)¥8.98B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)12.7
Beta0.57
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.02%
Share Statistics
EPS (TTM)155.28
Shares Outstanding8,760,000
10 Day Avg. Volume4,730
30 Day Avg. Volume5,400
Financial Highlights & Ratios
PEG Ratio2.14
Price to Book (P/B)1.12
Price to Sales (P/S)1.44
P/FCF Ratio15.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially lowers financial risk and gives management durable optionality: funds for R&D, equipment, dividends or opportunistic M&A without refinancing pressure. This conservatism strengthens resilience through cycles and preserves long-term strategic flexibility.
High Gross MarginsConsistent gross margins around 49–50% indicate durable product-level profitability, likely driven by instrument sales plus recurring consumables. Such structural margin strength supports operating cash generation and reinvestment capacity, underpinning sustained competitive returns.
Strong Cash ConversionFree cash flow converting close to reported earnings shows quality of reported profits and reliable internal funding for capex and dividends. Over the medium term this supports capital allocation without reliance on external debt, aiding long-term financial independence.
Bears Say
Uneven Revenue GrowthRevenue and profit swings (declines in some years, rebound in 2026) point to inconsistent demand or product cycle exposure. This undermines predictability for capacity planning and long-term investment, making durable growth planning and forecasting more challenging.
Volatile Cash FlowsMaterial year-to-year swings in operating and free cash flow reduce precision of capital allocation and increase the risk of funding shortfalls during downturns. Even with strong conversion on average, volatility complicates reliable dividend policy and multi-year R&D or expansion programs.
Moderate Returns On EquityROE in the mid-to-high single digits reflects modest efficiency of capital use given a debt-free base. Over time this suggests constrained shareholder return potential or under-deployed capital, limiting the company's ability to generate outsized equity returns absent higher growth.
Techno Medica Co., Ltd. News
6678 FAQ
What was Techno Medica Co., Ltd.’s price range in the past 12 months?
Techno Medica Co., Ltd. lowest stock price was ¥1830.00 and its highest was ¥2787.00 in the past 12 months.
What is Techno Medica Co., Ltd.’s market cap?
Techno Medica Co., Ltd.’s market cap is ¥16.79B.
When is Techno Medica Co., Ltd.’s upcoming earnings report date?
Techno Medica Co., Ltd.’s upcoming earnings report date is Aug 05, 2026 which is in 33 days.
How were Techno Medica Co., Ltd.’s earnings last quarter?
Techno Medica Co., Ltd. released its earnings results on May 11, 2026. The company reported ¥88.84 earnings per share for the quarter, beating the consensus estimate of N/A by ¥88.84.
Is Techno Medica Co., Ltd. overvalued?
According to Wall Street analysts Techno Medica Co., Ltd.’s price is currently Overvalued.
Does Techno Medica Co., Ltd. pay dividends?
Techno Medica Co., Ltd. pays a Annually dividend of ¥93 which represents an annual dividend yield of 3.02%. See more information on Techno Medica Co., Ltd. dividends here
What is Techno Medica Co., Ltd.’s EPS estimate?
Techno Medica Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Techno Medica Co., Ltd. have?
Techno Medica Co., Ltd. has 8,760,000 shares outstanding.
What happened to Techno Medica Co., Ltd.’s price movement after its last earnings report?
Techno Medica Co., Ltd. reported an EPS of ¥88.84 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.761%.
Which hedge fund is a major shareholder of Techno Medica Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6678
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Techno Medica Co., Ltd.
Techno Medica Co., Ltd. is a Japanese company that specializes in the entire lifecycle of in-vitro diagnostic analyzers, covering their research, development, manufacturing, distribution, and international trade. Their product portfolio includes automated systems for test tube preparation, urine aliquot, and RFID-based management solutions for both biological specimens and blood transfusions. The company also supplies a diverse range of analytical instruments for measuring blood gases, electrolytes, erythrocyte sedimentation rates, nutrient levels, sugar and acid content, and for performing urine chemistry tests. Furthermore, Techno Medica provides electronic medical charting systems, various pre-analytical devices, essential consumables, and comprehensive after-sales support. Established in 1987, the company's main office is located in Yokohama, Japan.
Technical Analysis
PHC Holdings Corp.
―
Eiken Chemical Co., Ltd.
―
Nihon Kohden Corporation
―
Japan Medical Dynamic Marketing, Inc.
―
Koken Ltd.
―
Options Prices
Currently, No data available
---